Study:
Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known which combination chemotherapy regimen is more
effective for urinary tract cancer.
Purpose:
Randomized phase III trial to compare the effectiveness of cisplatin plus
gemcitabine with or without paclitaxel in treating patients who have stage IV urinary tract
cancer.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer |
Drug: cisplatin
Drug: gemcitabine hydrochloride
Drug: paclitaxel |
Phase 3 |
Verified by
European Organization for Research and Treatment of Cancer
September, 2006
Sponsored by: European Organization for Research and Treatment of Cancer
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00022191
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-9001
United States
Joaquim Bellmunt, MD, PhD., Study Chair
Stephane Culine, MD., Study Chair
Michael Leahy, MBChB, FRACP, FRCP, FRC Path., Study Chair
Christoph Zielinski, MD., Study Chair
Malcolm J. Moore, MD., Study Chair
David C. Smith, MD., Study Chair
Andreas Boehle, MD., Study Chair
Jose Baselga, MD., Study Chair
Michael Leahy, MBChB, FRACP, FRCP, FRC Path., Study Chair